Bionano Genomics, Inc. (BNGO) — 8-K Filings

8-K Filings (22)

• Bionano Genomics Files 8-K with Material Agreement — Sep 18, 2025 Risk: medium
  On September 16, 2025, Bionano Genomics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statement
• Bionano Genomics Announces Board & Executive Changes — Jun 13, 2025 Risk: medium
  Bionano Genomics, Inc. announced on June 10, 2025, changes related to its board of directors and executive compensation. The filing details the departure of cer
• Bionano Genomics Files 8-K for Material Agreement — Feb 21, 2025 Risk: low
  On February 21, 2025, Bionano Genomics, Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The company, incorporated i
• Bionano Genomics Terminates Material Agreement — Feb 10, 2025 Risk: medium
  Bionano Genomics, Inc. announced on February 4, 2025, the termination of a material definitive agreement. The company, incorporated in Delaware, filed this 8-K
• Bionano Genomics Files 8-K on Security Holder Rights — Jan 27, 2025 Risk: medium
  Bionano Genomics, Inc. filed an 8-K on January 24, 2025, reporting material modifications to the rights of security holders and amendments to its articles of in
• Bionano Genomics Reports on Shareholder Vote — Jan 16, 2025 Risk: low
  Bionano Genomics, Inc. filed an 8-K on January 16, 2025, reporting on matters submitted to a vote of security holders on January 15, 2025. The filing details th
• Bionano Genomics Files 8-K on Financials — Jan 13, 2025 Risk: low
  Bionano Genomics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition, as well as financial statements and exh
• Bionano Genomics Files 8-K with Material Agreement — Jan 6, 2025 Risk: medium
  On January 3, 2025, Bionano Genomics, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and reported other eve
• Bionano Genomics Files 8-K with Key Agreements and Equity Sales — Jan 3, 2025 Risk: medium
  On December 31, 2024, Bionano Genomics, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, engaged
• Bionano Genomics Files 8-K on Shareholder Votes — Dec 2, 2024 Risk: low
  Bionano Genomics, Inc. filed an 8-K on November 27, 2024, to report on matters submitted to a vote of its security holders. The filing details the company's cor
• Bionano Genomics Files 8-K on Financials — Nov 13, 2024 Risk: medium
  Bionano Genomics, Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition, as well as financial statements and ex
• Bionano Genomics Enters Material Definitive Agreement — Oct 31, 2024 Risk: medium
  Bionano Genomics, Inc. announced on October 30, 2024, that it entered into a Material Definitive Agreement. The company also disclosed information related to Re
• Bionano Genomics Files 8-K on Financials — Oct 10, 2024 Risk: medium
  Bionano Genomics, Inc. filed an 8-K on October 10, 2024, reporting on its results of operations and financial condition. The filing includes financial statement
• Bionano Genomics CFO Departs Amid Strategic Shifts — Sep 9, 2024 Risk: medium
  Bionano Genomics, Inc. announced on September 4, 2024, the departure of its Chief Financial Officer, Michael J. Mauboussin. The company has appointed Christophe
• Bionano Genomics Faces Nasdaq Delisting Warning — Jul 18, 2024 Risk: medium
  Bionano Genomics, Inc. received a notification on July 12, 2024, from the Nasdaq Stock Market indicating that the company is not in compliance with the minimum
• Bionano Genomics Files 8-K: Material Agreement & Equity Sales — Jul 8, 2024 Risk: medium
  On July 4, 2024, Bionano Genomics, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and pro
• Bionano Genomics Holds 2024 Annual Meeting — Jun 21, 2024 Risk: low
  Bionano Genomics, Inc. announced on June 18, 2024, that it held its 2024 Annual Meeting of Stockholders. During the meeting, stockholders voted on several propo
• Bionano Genomics Announces Material Agreements and Financial Obligations — May 28, 2024 Risk: medium
  On May 23, 2024, Bionano Genomics, Inc. entered into a Material Definitive Agreement and also terminated a Material Definitive Agreement. The company also incur
• Bionano Genomics Files 8-K for Financial Statements — Apr 8, 2024 Risk: low
  On April 8, 2024, Bionano Genomics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disclosures
• Bionano Genomics Files 8-K with Material Agreement Details — Apr 5, 2024 Risk: low
  On April 4, 2024, Bionano Genomics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures and f
• Bionano Genomics Reports Material Agreement on Feb 27 — Feb 28, 2024 Risk: medium
  Bionano Genomics, Inc. filed an 8-K on February 27, 2024, to report an entry into a material definitive agreement and provide Regulation FD disclosure. The comp
• Bionano Genomics Registers Common Stock & Warrants on Nasdaq — Jan 8, 2024
  Bionano Genomics, Inc. filed an 8-K on January 8, 2024, to register its Common Stock, $0.0001 par value per share, and Warrants on The Nasdaq Stock Market LLC u

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX